TOKYO and MUNICH | January 19, 2026 — Daiichi Sankyo and AstraZeneca announced that the European Medicines Agency (EMA) has validated a Type II variation application for ENHERTU® (trastuzumab deruxtecan) in combination with pertuzumab as a first-line treatment for adults with unresectable or metastatic HER2-positive breast cancer. The validation confirms dossier completeness and formally initiates scientific review by the Committee for Medicinal Products for Human Use (CHMP), based on compelling Phase 3 DESTINY-Breast09 data demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus the current first-line standard of care.
Science Significance
The application is anchored in results from DESTINY-Breast09, a large, global, randomized Phase 3 trial evaluating ENHERTU plus pertuzumab against taxane, trastuzumab and pertuzumab (THP). ENHERTU is a HER2-directed antibody–drug conjugate (ADC) built on Daiichi Sankyo’s DXd ADC Technology, coupling a HER2 monoclonal antibody with a topoisomerase I inhibitor payload via cleavable linkers. This design enables potent tumor-selective cytotoxicity while maintaining systemic tolerability. In DESTINY-Breast09, the combination regimen delivered superior PFS, signaling a potential paradigm shift in first-line HER2-positive metastatic breast cancer, where outcomes have plateaued for more than a decade despite HER2-targeted advances.
Regulatory Significance
EMA validation marks a critical post-authorization lifecycle milestone, triggering CHMP’s formal scientific assessment of benefit–risk. A Type II variation reflects a major change to the marketing authorization, typically requiring robust clinical evidence and comprehensive quality, nonclinical, and pharmacovigilance data. For cGxP stakeholders, the process underscores the importance of GCP-compliant Phase 3 data, manufacturing consistency under GMP, and integrated safety monitoring for complex biologics such as ADCs. The EU review follows a recent U.S. approval for the same first-line indication, highlighting regulatory convergence and the growing role of global evidence packages in accelerating patient access.
Business Significance
Advertisement
Commercially, EU validation strengthens the strategic value of ENHERTU within the long-standing Daiichi Sankyo–AstraZeneca collaboration. ENHERTU is already approved across multiple HER2-driven indications and geographies, and first-line metastatic breast cancer represents a large, high-impact market. A successful EU outcome could expand market leadership, reinforce the companies’ ADC portfolios, and validate continued investment in DXd platform innovations. For AstraZeneca, the milestone supports its broader oncology strategy centered on next-generation biologics, while for Daiichi Sankyo it underscores the global reach of its in-house discovery and manufacturing capabilities.
Patients’ Significance
For patients, the potential approval addresses a critical unmet need. HER2-positive metastatic breast cancer is aggressive, and despite targeted therapies, most patients experience disease progression within two years on current first-line regimens. DESTINY-Breast09 demonstrated that ENHERTU plus pertuzumab can meaningfully delay progression, offering the prospect of longer disease control and improved quality of life. Earlier access to a more effective first-line option could also reduce the proportion of patients who never reach subsequent lines of therapy due to rapid progression or decline.
Policy Significance
At a policy level, the validation reflects Europe’s commitment to science-led regulatory decision-making and timely evaluation of transformative oncology therapies. ADCs sit at the intersection of biologics and cytotoxics, demanding stringent regulatory oversight across development, manufacturing, and post-marketing surveillance. The ENHERTU review exemplifies how robust clinical evidence and platform maturity can support expedited consideration of therapies that may redefine standards of care, aligning with EU goals to improve cancer outcomes while safeguarding patient safety.
EMA’s validation of the Type II variation for ENHERTU® plus pertuzumab marks a pivotal step toward redefining first-line treatment for HER2-positive metastatic breast cancer in Europe. Grounded in strong Phase 3 evidence, supported by global regulatory momentum, and enabled by advanced ADC technology, the application highlights how innovation, quality, and compliance converge to advance patient care. For the cGxP community, the development underscores the central role of clinical excellence, regulatory rigor, and lifecycle management in bringing next-generation oncology therapies to patients who urgently need better options.
Source: Daiichi Sankyo / AstraZeneca press release
